Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

8022Background: KRd is approved for treatment of RRMM patients (pts). Under the approved KRd regimen, carfilzomib is given twice weekly (20/27 mg/m2; 10-min IV infusion). Here we present updated re...